Add this result to my export selection Secukinumab (Cosentyx®) accepted for use within NHS Scotland for treatment of active non-radiographic axial spondyloarthritis Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Approval is based on a randomised phase III study, in which secukinumab, compared with placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Daratumumab subcutaneous injection (Darzalex®) accepted for use within NHS Scotland Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Following submission under the orphan medicine process, SMC has approved daratumumab in combination with bortezomib, thalidomide and dexamethasone for treatment of adult patients with newly diagnosed... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Melatonin prolonged-release (Slenyto®) not recommended for use within NHS Scotland for treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Slenyto® compared with placebo, increased total sleep time and sleep onset latency in children who had an insufficient response to sleep hygiene measures. However, the company did not present a... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Brentuximab vedotin (Adcetris®) accepted for use within NHS Scotland for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Approval based on phase III study, in which brentuximab in combination with cyclophosphamide, doxorubicin and prednisone was associated with a significant improvement in progression-free survival vs. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Brigatinib (Alunbrig®) accepted for use within NHS Scotland for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Approved for patients previously not treated with an ALK inhibitor; offering an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Entrectinib (Rozlytrek®) accepted for use within NHS Scotland for treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC) Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 18 January 2021 Approved for patients not previously treated with ROS1 inhibitors; based on a phase II study in patients with ROS1-positive advanced NSCLC, in which the objective response rate was 72%. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Upadacitinib (Rinvoq®) accepted for restricted use within NHS Scotland for treatment of moderate to severe active rheumatoid arthritis Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 08 February 2021 Treatment is restricted to patients with severe disease (DAS28> 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in severe disease inadequately... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Ravulizumab (Ultomiris) accepted for restricted use within NHS Scotland for treatment of paroxysmal nocturnal haemoglobinuria Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 08 February 2021 Treatment is restricted patients with haemolysis with clinical symptom(s) indicative of high disease activity and/or patients who are clinically stable after having been treated with eculizumab for... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Ozanimod (Zeposia) accepted for restricted use within NHS Scotland for treatment of relapsing remitting multiple sclerosis Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 08 February 2021 Treatment is restricted to adult patients with relapsing remitting multiple sclerosis, with active disease as defined by clinical or imaging features, who are requesting an oral treatment. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Leuprorelin acetate (Prostap DCS) accepted for use within NHS Scotland for early stage breast cancer Source: Scottish Medicines Consortium - SMC (Remove filter) Published by Scottish Medicines Consortium, 08 February 2021 Leuprorelin offers an additional adjuvant treatment choice in the therapeutic class of gonadotropin-releasing hormone analogues for endocrine responsive early stage breast cancer in pre- and... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)